sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Welcomes William Monteith to the Board of Directors
Paris, June 3, 2024 - GenSight Biologics, a biopharmaceutical company specializing in gene therapies for retinal and neurodegenerative diseases, announces the appointment of William Monteith to its Board of Directors. Monteith took office on May 29, 2024 as an independent Director.
William Monteith brings 43 years of experience in pharmaceutical manufacturing, having held various management positions at Wyeth, Sandoz, Dendreon and Hitachi Chemical. His appointment aims to strengthen the production of LUMEVOQ, a gene therapy for Leber's hereditary optic neuropathy (LHON).
Ivan Tortet, previously interim Financial Director, is appointed Administrative and Financial Director. Tortet actively participated in the recent financing of GenSight Biologics, with experience at Deloitte and various growing high-tech companies.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.